{"id":147306,"date":"2022-09-30T19:23:45","date_gmt":"2022-10-01T00:23:45","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/09\/analysis-eisais-trial-success-raises-hope-for-alzheimers-prevention"},"modified":"2022-09-30T19:23:45","modified_gmt":"2022-10-01T00:23:45","slug":"analysis-eisais-trial-success-raises-hope-for-alzheimers-prevention","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/09\/analysis-eisais-trial-success-raises-hope-for-alzheimers-prevention","title":{"rendered":"Analysis: Eisai\u2019s trial success raises hope for Alzheimer\u2019s prevention"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/analysis-eisais-trial-success-raises-hope-for-alzheimers-prevention2.jpg\"><\/a><\/p>\n<p>CHICAGO, Sept 30 (Reuters) \u2014 Clear evidence this week that Eisai <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/4523.T\" target=\"_blank\" class=\"\">(4523.T)<\/a> and Biogen\u2019s <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/BIIB.O\" target=\"_blank\" class=\"\">(BIIB.O)<\/a> drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer\u2019s researchers toward a tantalizing goal \u2014 preventing dementia even before symptoms start.<\/p>\n<p>Lecanemab is an antibody that targets and removes toxic clumps of a protein called amyloid beta that accumulate in the brains of patients with Alzheimer\u2019s. Results from the companies\u2019 1,800-patient trial released on Tuesday <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eisai-says-alzheimers-drug-succeeds-slowing-cognitive-decline-2022-09-27\/\" class=\"\">showed convincingly<\/a> that doing so also slows the advance of the mind-robbing disease.<\/p>\n<p>In volunteers with mild cognitive impairment and early stage dementia, the drug showed a 27% reduction in cognitive decline after 18 months compared with those who got a placebo.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHICAGO, Sept 30 (Reuters) \u2014 Clear evidence this week that Eisai (4523.T) and Biogen\u2019s (BIIB.O) drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer\u2019s researchers toward a tantalizing goal \u2014 preventing dementia even before symptoms start. Lecanemab is an antibody that targets and removes toxic clumps of a protein called [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-147306","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/147306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=147306"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/147306\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=147306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=147306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=147306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}